Nexalin Technology, Inc. (NXL), Wednesday announced positive clinical study data regarding feasibility, safety, and efficacy of transcranial alternating current dynamic frequency stimulation as an add-on treatment for patients with major depressive disorder, commonly known as clinical depression.
The study, published in Brain Stimulation, involved 66 participants, who received 20 sessions of either the company's non-invasive Deep Intracranial Frequency Stimulation technology in combination with escitalopram or Lexapro, or sham stimulation, for 40 minutes.
At the end of four weeks, two-thirds of participants who received the combination therapy showed improvement compared to one-third of patients who received medication only, the company stated.
Currently, Nexalin's stock is moving up 8.81 percent, to $2.46 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.